Please contact us by email at: info@solmedx.com or by providing the information below.
Dr. Sam Sofer can be reached directly by email at: ssofer@solmedx.com.
At present, clinical trials are under way with patients with Hepatitis C and a control group (University of Medicine & Dentistry of New Jersey IRB Protocol No. 0120090320). The purpose of the clinical trial is to identify patients who have an imbalanced ROX and
examine their progress during the course of treatment with interferon and ribavirin
supplements. By quantifying the patient's ROX delivery system, this study identifies
which patients are non-responders to interferon/Ribavirin treatment.
PLANNED CLINICAL TRIALS:
ALS: Imbalanced ROX at the motor neuron leads to oxidative damage to the motor
neuron and surrounding tissue.
Alzheimer's, Huntington's, MS, and other neurodegenerative diseases: Imbalanced
ROX for nervous system leads to oxidative damage of nerve tissue and surroundings.
Cancer: A tumor cannot be contained if there is insufficient ROX; A cancer patient with
sufficient ROX can prevent a tumor from spreading by destroying any metastasized
cancer cells.
Complex Regional Pain Syndrome (CRPS): Out of balance ROX allows free radicals to
cause pain.
Diabetes: If not enough ROX is delivered for glucose to convert to energy, added
insulin will not control the patient's sugar level.
HIV/AIDS: When a T-cell recognizes a virus, it recruits a critical mass of ROX to destroy
the virus. Insufficient ROX would not allow a critical mass to focus on the virus, allowing
it to spread out and destroy the T-cell and surrounding tissue.
Parkinson's Disease: If less than a critical mass of ROX exists, radicals will be released
at the surrounding tissues, causing widespread damage. This can begin a chain of
events leading to PD.
Rheumatoid Arthritis (RA) and other auto-immune diseases: Insufficient ROX allows for
the indiscriminate spread of radical oxygen species, thus damaging surrounding tissues.
Solmedx can be found online under the following tags: interferon treatment, patient blood samples,ROX (reservoir oxygen capacity), Cancer, innate immune viability,AIDs, BOX, blood cell oxygen capacity,
adaptive immune system strength,proper medication dosage, clinical studies,Hepatitis C, Diabetes, patient injury and drug toxicity Alzheimer's, ALS,
and other neurodegenerative diseases; Cancer; Diabetes; HIV/AIDS, Huntington's
Disease, Parkinson's Disease (PD), Rheumatoid Arthritis (RA) and other auto-immune
diseases; and Complex Regional Pain Syndrome (CRPS)]
